Elkedonia CEO Advocates for Precision Medicine at the 1st European Neuroscience Innovation Forum

Delphine Charvin highlighted Elkedonia’s pioneering neuroplastogen approach and its patient-first strategy that leverages AI and biomarkers to overcome current antidepressant limitations. The panel underscored the company’s commitment to putting patients at the heart of neuropsychiatric research to ensure rapid, effective, and targeted therapies.